Peng Yang

age ~71

from Huntington Station, NY

Get Report

Also known as:

Connected to:

Peng Yang Phones & Addresses

Novel Cannabinoid Receptor 2 (Cb2) Inverse Agonists And Therapeutic Potential For Multiple Myeloma And Osteoporosis Bone Diseases
view source
US Patent:

20130172388, Jul 4, 2013
Filed:

Dec 14, 2012
Appl. No.:

13/715603
Inventors:

University of Pittsburgh -- Of the Commonwealth System of Higher Education - Pittsburgh PA, US
Rentian Feng - Pittsburgh PA, US
Peng Yang - Pittsburgh PA, US
Assignee:

University of Pittsburgh -- Of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:

C07C 311/48
C07D 203/08
C07C 69/78
C07C 311/05
C07D 211/06
C07C 233/36
C07C 311/20
C07C 311/29
C07D 235/12
C07C 233/40
US Classification:

514331, 564157, 564155, 564158, 546231, 564 92, 564 89, 564123, 564192, 564182, 564 99, 5483094, 548966, 560107, 564 82, 514616, 514604, 514613, 514625, 514617, 514605
Abstract:

Cannabionid receptor-2 inverse antagonists include compounds represented by Formula IV, or a pharmaceutically acceptable salt thereof:wherein: Rand Rare independently H, alkyl, or alkenyl; Ris alkyl, alkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl; Rand Rare independently a bond, alkylenyl, or alkenylenyl; each Rand Ris independently selected from the group consisting of OH, F, Cl, Br, I, (C-C)alkyl, alkoxy, amino, COOH, CONH, SOH, POH, CN, SH, NOand CF; and p and q are independently 0, 1, 2, 3, 4, or 5. Such compounds may be used to treat osteoporosis or multiple myeloma.

Novel Cannabinoid Receptor Cb2 Ligand 4-(Aminomethyl)-N, N-Dialkylanilines
view source
US Patent:

20200270205, Aug 27, 2020
Filed:

May 11, 2020
Appl. No.:

16/872138
Inventors:

- Pittsburgh PA, US
Abdulrahman Almehizia - Pittsburgh PA, US
Peng Yang - Pittsburgh PA, US
Assignee:

UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION - Pittsburgh PA
International Classification:

C07C 311/29
C07D 405/12
C07D 409/12
C07D 333/34
C07D 333/38
C07C 311/13
C07C 311/18
C07D 401/12
C07D 241/44
A61P 19/10
A61P 35/00
C07D 213/42
C07D 317/58
Abstract:

Disclosed herein are novel cannabionid receptor-2 (CB2) agonists and inverse agonists represented by Formula (I), and method of modulating the activity of CB2 by contacting the CB-2 receptor with a compound of Formula (I). Also, disclosed are methods for treating multiple myeloma or osteoporosis in a mammal in need thereof by modulating the activity of a cannabinoid receptor-2 (CB2).

Novel Cannabinoid Receptor Cb2 Ligand 4-(Aminomethyl)-N,N-Dialkylanilines
view source
US Patent:

20180141902, May 24, 2018
Filed:

Jun 17, 2016
Appl. No.:

15/580539
Inventors:

- Pittsburgh PA, US
Peng Yang - Pittsburgh PA, US
Assignee:

UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION - Pittsburgh PA
International Classification:

C07C 311/29
A61P 35/00
A61P 19/10
C07C 311/18
C07D 333/38
C07D 241/44
C07C 311/13
C07D 333/34
C07D 409/12
C07D 401/12
C07D 213/42
C07D 317/58
C07D 405/12
Abstract:

Disclosed herein are novel cannabinoid receptor-2 (CB2) agonists and inverse agonists represented by Formula (I), and method of modulating the activity of CB2 by contacting the CB-2 receptor with a compound of Formula (I). Also, disclosed are methods for treating multiple myeloma or osteoporosis in a mammal in need thereof by modulating the activity of a cannabinoid receptor-2 (CB2).

Novel Cannabinoid Receptor 2 (Cb2) Inverse Agonists And Therapeutic Potential For Multiple Myeloma And Osteoporosis Bone Diseases
view source
US Patent:

20170001949, Jan 5, 2017
Filed:

May 31, 2016
Appl. No.:

15/169725
Inventors:

- Pittsburgh PA, US
Peng YANG - Pittsburgh PA, US
Rentian FENG - Pittsburgh PA, US
Assignee:

University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:

C07C 233/40
C07D 295/135
Abstract:

Cannabinoid receptor-2 inverse antagonists include compounds represented by Formula IV, or a pharmaceutically acceptable salt thereof:wherein: Rand Rare independently H, alkyl, or alkenyl; Ris alkyl, alkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl; Rand Rare independently a bond, alkylenyl, or alkenylenyl; each Rand Ris independently selected from the group consisting of OH, F, Cl, Br, I, (C-C)alkyl, alkoxy, amino, COOH, CONH, SOH, POH, CN, SH, NOand CF; and p and q are independently 0, 1, 2, 3, 4, or 5. Such compounds may be used to treat osteoporosis or multiple myeloma.

Novel Cannabinoid Receptor 2 (Cb2) Inverse Agonists And Therapeutic Potential For Multiple Myeloma And Osteoporosis Bone Diseases
view source
US Patent:

20140296294, Oct 2, 2014
Filed:

Jun 16, 2014
Appl. No.:

14/305941
Inventors:

- Pittsburgh PA, US
Peng YANG - Pittsburgh PA, US
Rentian FENG - Pittsburgh PA, US
International Classification:

C07D 211/06
C07C 311/20
C07C 311/05
C07C 233/40
US Classification:

514331, 514616, 514604, 514613, 514625, 514617, 514605
Abstract:

Cannabionid receptor-2 inverse antagonists include compounds represented by Formula IV, or a pharmaceutically acceptable salt thereof: